KEY EVENTS IN Q1 2024
- Nomination Committee appointed for the Annual General Meeting 2024
- Orviglance review article is published in Investigative Radiology
Ascelia Pharma secures financing of up toSEK 35 million
KEY EVENTS AFTER THE PERIOD
- SPARKLE image reading completed with expected headline results first half of
May 2024 Ascelia Pharma draws downSEK 15 million second tranche under existing loan- Primary endpoint successfully met with strong headline results in Orviglance phase 3 study
- Bulletin from the Annual General Meeting in
Ascelia Pharma AB on6 May 2024 Ascelia Pharma hosts Investor Update: Bringing Orviglance to Patients
FINANCIAL SUMMARY Q1 (Jan-Mar) 2024
- Operating result of
SEK -16.7M (SEK -36.7M ) - Earnings per share of
SEK -0.5 (SEK -1.1 ) - Cash flow from operations of
SEK -15.0M (SEK -37.5M ) - Liquid assets and marketable securities of
SEK 26.5M (SEK 111.4M )
“On
We will now focus on bringing Orviglance through the regulatory submission and approval process. In parallel, we will continue to advance launch readiness and dialogue with potential commercialization partners to make Orviglance available to patients who need high-quality liver imaging without gadolinium related safety risk. Submission of the New Drug Application (NDA) to the
We look very much forward to executing on the opportunities ahead for
A presentation for analysts, investors and media will be held today 16 May at
To participate via teleconference, please register through this link. After registration, you will be provided with phone numbers and a conference ID to access the conference.
It will also be possible to access the audiocast afterwards at the same address or on the website of Ascelia Pharma: https://www.ascelia.com/ir-media/.
© Modular Finance, source